Sanofi Pasteur Expands Recall of H1N1 Vaccine
Sanofi Pasteur (Lyon, France) has recalled an additional six lots of its Influenza A (H1N1) 2009 Monovalent Vaccine in prefilled syringes after routine testing found that the antigen content had declined below the specification limit.
Sanofi Pasteur (Lyon, France) has recalled an additional six lots of its Influenza A (H1N1) 2009 Monovalent Vaccine in prefilled syringes after routine testing found that the antigen content had declined below the specification limit.
In December 2009, the company recalled 4 lots of its H1N1 pediatric vaccine in prefilled syringes after routine stability testing determined that those lots no longer met the potency specification.
As with the December recall, the FDA has stated that there are no safety concerns related to the recall and that individuals immunized with these lots do not need re-immunization.
Previous coverage
Sanofi Recalls 800,000 Doses of H1N1 (Swine) Flu Vaccine for Children
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
